Skip to main content

Table 1 Baseline patient demographics in the mistletoe and non-mistletoe groups

From: Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study

Variables MG (n = 15) NMG (n = 37) P-value
Age (years) 68 (38–83) 67 (46–86) 0.864
Sex    0.525
 Male 9 (60.0) 26 (70.3)  
 Female 6 (40.0) 11 (29.7)  
BMI (kg/m2) 23.4 (20.8–28.3) 24.4 (15.1–31.5) 0.473
ASA score    0.254
 1 0 4 (10.8)  
 2 15 (100) 30 (81.1)  
 Unknown 0 3 (8.1)  
Past history    
 Diabetes 5 (33.3) 8 (21.6) 0.483
 Cardiovascular disease 7 (46.7) 18 (48.6) 0.897
 Others 5 (33.3) 13 (35.1) 0.902
Baseline tumor markers    
 CEA (ng/mL) 2.9 (0.5–43.7) 2.9 (0.6–44.9) 0.992
 CA 19-9 (U/mL) 4.2 (1.2–184.7) 12.1 (1.2–1222.8) 0.010†,**
Tumor distance from the AV (cm) 3.6 (0–10.0) 6.0 (2.0–10.0) 0.008†,**
MRF involvement    0.314
 Yes 10 (66.7) 19 (51.4)  
 No 5 (33.3) 18 (48.6)  
cT before NCRT    0.412
 cT2 1 (6.7) 0  
 cT3 12 (80.0) 32 (86.5)  
 cT4 2 (13.3) 5 (13.5)  
cN before NCRT    0.086
 cN0 0 3 (8.1)  
 cN1 7 (46.7) 6 (16.2)  
 cN2 8 (53.3) 28 (75.7)  
Baseline clinical stage (AJCC 8th edition)    0.548
 Stage II 0 3 (8.1)  
 Stage III 15 (100) 34 (91.9)  
  1. Data are presented as median (range) for continuous variables and n (%) for categorical variables
  2. Mann–Whitney test; chi-square test or Fisher’s exact test; **statistical significance (P < 0.05)
  3. MG, mistletoe group; NMG, non-mistletoe group; BMI, body mass index; ASA, American Society of Anesthesiologist; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; AV, anal verge; MRF, mesorectal fascia; NCRT, neoadjuvant chemoradiotherapy; AJCC, American Joint Committee on Cancer